The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis. in Women's health reports (New Rochelle, N.Y.) / Womens Health Rep (New Rochelle). 2022 Feb 2;3(1):162-171. doi: 10.1089/whr.2021.0063. eCollection 2
2022
ASL Città di Torino
AOU Città della Salute di Torino
AO Ordine Mauriziano
Tipo pubblicazione
Journal Article
Autori/Collaboratori (26)Vedi tutti...
Zagni E
Novartis Farma S.p.A, Origgio, Italy.
Orsenigo R
Novartis Farma S.p.A, Origgio, Italy.
Fiocchi M
Novartis Farma S.p.A, Origgio, Italy.
et alii...
Abstract
Background: Phenotypic features and outcome differences between sexes have been reported in psoriatic arthritis (PsA). However, little is known about sex differences in effectiveness of biologics in clinical practice. Methods: Post hoc gender analysis of the CHRONOS, a multicenter, noninterventional, retroprospective Italian real-world study assessing 6-month and 1-year effectiveness of biologics for PsA. Results: Eligible patients were 399, 43.1% men. Sociodemographic characteristics, type of arthritis, baseline Disease Activity Score 28 joints (DAS28), and duration of biologic treatment were rather homogeneous. More men were overweight/obese and naive to biologics. The most frequently used biologics were TNF-inhibitors and secukinumab in both sexes. DAS28 responders were 72.7% (women) and 70.5% (men) at 6 months, and 68.0% in both sexes at 1 year. American College of Rheumatology (ACR) response showed a trend for men versus women to achieve more frequently ACR50 (32.6% vs. 26.5% at 6 months; 34.9% vs. 20.0% at 1 year) and ACR70 (22.3% vs. 12.4% at 6 months and 25.0% vs. 13.0% at 1 year). Global satisfaction with treatment at enrollment and after 6 months was slightly higher among men [mean (standard deviation) Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) score: 68.6 (18.6) and 69.9 (18.2), respectively] than women [65.3 (18.2), 66.2 (18.5)]. Conclusions: Overall response to biologics for PsA was rather favorable. With similar baseline disease severity, men appear to have a somewhat earlier and better response with higher treatment satisfaction.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 35262053
DOI : 10.1089/whr.2021.0063
Keywords
real-world evidence; gender differences; observational study; psoriatic arthritis; effectiveness; biologics;